Brain Disorders & Therapy

Khanna VK. Deep Brain Stimulation. InImplantable Medical Electronics 2016 (pp. 309-329). Springer International Publishing.

Hall DA, Leehey MA, Berry-Kravis E, Hagerman RJ. Treatment and Management of FXTAS. InFXTAS, FXPOI, and Other Premutation Disorders 2016 (pp. 181-197). Springer International Publishing.

Hagerman RJ, Hagerman P. Fragile X-associated tremor/ataxia syndrome [mdash] features, mechanisms and management. Nature Reviews Neurology. 2016 Jul 1;12(7):403-12.

Braga Neto P, Pedroso JL, Kuo SH, Junior M, França C, Teive HA, Barsottini OG. Current concepts in the treatment of hereditary ataxias. Arquivos de neuro-psiquiatria. 2016 Mar;74(3):244-52.

Oyama G, Umemura A, Shimo Y, Nishikawa N, Nakajima A, Jo T, Nakajima M, Ishii H, Yamada D, Takanashi M, Arai H. Posterior Subthalamic Area Deep Brain Stimulation for Fragile X–Associated Tremor/Ataxia Syndrome. Neuromodulation: Technology at the Neural Interface. 2014 Dec 1;17(8):721-3.

Muzar Z, Lozano R. Current research, diagnosis, and treatment of fragile X-associated tremor/ataxia syndrome. Intractable & rare diseases research. 2014 Nov 30;3(4):101-9.

Besterman AD, Wilke SA, Mulligan TE, Allison SC, Hagerman R, Seritan AL, Bourgeois JA. Towards an understanding of neuropsychiatric manifestations in fragile X premutation carriers. Future neurology. 2014 Mar;9(2):227-39.

Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. The Lancet Neurology. 2013 Aug 31;12(8):786-98.

Fassio A, Fadda M, Benfenati F. Molecular Machines Determining the Fate of Endocytosed Synaptic Vesicles in Nerve Terminals. Frontiers in synaptic neuroscience. 2016;8.

Smith‐Trunova S, Prithviraj R, Spurrier J, Kuzina I, Gu Q, Giniger E. Cdk5 regulates developmental remodeling of mushroom body neurons in Drosophila. Developmental Dynamics. 2015 Dec 1;244(12):1550-63.

Shah K, Lahiri DK. A Tale of the Good and Bad: Remodeling of the Microtubule Network in the Brain by Cdk5. Molecular neurobiology. 2016 Mar 5:1-4.

Shi C, Viccaro K, Lee HG, Shah K. Cdk5–Foxo3 axis: initially neuroprotective, eventually neurodegenerative in Alzheimer's disease models. J Cell Sci. 2016 May 1;129(9):1815-30.

Oren Y, Nachshon A, Frishberg A, Wilentzik R, Gat-Viks I. Linking traits based on their shared molecular mechanisms. eLife. 2015 Mar 17;4:e04346.

Rahmati M, Taherabadi SJ, Mehrabi M. Decreased activity in neuropathic pain form and gene expression of cyclin-dependent kinase5 and glycogen synthase Kinase-3 Beta in Soleus muscle of Wistar male rats. Iranian Red Crescent Medical Journal. 2015 Jun;17(6).

Singh BM, Mohanvir K, Nishit G, Kumar BV. RESEARCH AND REVIEWS: JOURNAL OF MEDICAL AND HEALTH SCIENCES.

Neves-Carvalho A, Logarinho E, Freitas A, Duarte-Silva S, do Carmo Costa M, Silva-Fernandes A, Martins M, Serra SC, Lopes AT, Paulson HL, Heutink P. Dominant negative effect of polyglutamine expansion perturbs normal function of ataxin-3 in neuronal cells. Human molecular genetics. 2015 Jan 1;24(1):100-17.

Lu X. Bilateral Neural Control of Visually Guided Hand Movement. Brain Disord Ther. 2014;3:e110.

Sriram S. Ijppr.

Shandal V, Luo JJ. Clinical manifestations of isolated elevated homocysteine-induced peripheral neuropathy in adults. Journal of clinical neuromuscular disease. 2016 Mar 1;17(3):106-9.

Luo JJ, Bumanlag F, Ansari R, Tang YM, Dun NJ. Central somatosensory conduction slowing in adults with isolated elevated plasma level of homocysteine. Neuroimmunology and Neuroinflammation. 2015 Jan 1;2(1):26-.